ArticleThe European respiratory journal2022
Short-acting β
Article in The European respiratory journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Adverse Outcomes Associated With Short-Acting Beta-Agonist Overuse in Asthma: A Systematic Review and Meta-Analysis.Allergy · 2025Pooled it
- Pooled it
- Perceptions, attitudes, and behaviors of asthma patients towards the use of short-acting β2-agonists: A systematic review.PloS one · 2023Pooled it
- Trial
- Article
- Article
- Worsening Asthma Outcomes in Australian Adults: A Comparison of Stratified Sample Surveys in 2012 and 2021.The Medical journal of Australia · 2026Article
- BetaFrontiers in medicine · 2026Review
- A current assessment of family physicians' knowledge and attitudes toward asthma management in primary care in Turkey according to the GINA strategy report.NPJ primary care respiratory medicine · 2025Article
- Article
- Characteristics and management of patients attending primary asthma clinics in primary health care in the Kingdom of Bahrain: A cross-sectional study.Journal of family medicine and primary care · 2025Article
- Guideline-based asthma treatment in Asia: Insights from a robust time-in-state model.The journal of allergy and clinical immunology. Global · 2025Article
- The Feasibility and Impact of Implementing Interventions to Reduce Short-Acting βAdvances in therapy · 2025Review
- Guideline-driven and dependable management of asthma: an evidence-based systematic review.Annals of medicine and surgery (2012) · 2025Article
- Optimising long-term management in acute asthma presentations to the emergency department: an interview study on patient beliefs.BMJ open respiratory research · 2025Article
- Burden of illness among patients with asthma prescribed inhaled corticosteroids/long-acting βNPJ primary care respiratory medicine · 2025Article
- Perceptions, practices, and experiences of asthma patients and community pharmacists on short-acting beta-2 agonists inhaler use: A qualitative study.Journal of pharmaceutical policy and practice · 2025Article
- Development of an asthma health-care burden score as a measure of severity and predictor of remission in SARP III and U-BIOPRED: results from two major longitudinal asthma cohorts.The Lancet. Respiratory medicine · 2025Article
- Prospects for the development of the electronic prescription system in the conditions of the modern pharmaceutical market of Russia.BMC health services research · 2024Article
- The Reliever Reliance Test: evaluating a new tool to address SABA over-reliance.NPJ primary care respiratory medicine · 2024Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo gain a global perspective on short-acting β
methodsSABINA III was a cross-sectional study that employed electronic case report forms at a study visit (in primary or specialist care) to record prescribed medication(s), over-the-counter (OTC) SABA purchases and clinical outcomes in asthma patients (≥12 years old) during the past 12 months. In patients with ≥1 SABA prescriptions, associations of SABA with asthma symptom control and severe exacerbations were analysed using multivariable regression models.
resultsOf 8351 patients recruited (n=6872, specialists; n=1440, primary care), 76.5% had moderate-to-severe asthma and 45.4% experienced ≥1 severe exacerbations in the past 12 months. 38% of patients were prescribed ≥3 SABA canisters; 18.0% purchased OTC SABA, of whom 76.8% also received SABA prescriptions. Prescriptions of 3-5, 6-9, 10-12 and ≥13 SABA canisters (
conclusionsThis study indicates an association between high SABA prescriptions and poor clinical outcomes across a broad range of countries, healthcare settings and asthma severities, providing support for initiatives to improve asthma morbidity by reducing SABA overreliance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.